Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Fair Value

Margin Of Safety %

Put/Call OI Ratio

0.2

Float Short​ %​

23.88

EPS 1 Diff

-0.05

EPS Year Diff

0.06

Ticker: AVXL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-09-06AVXL5.140.230.1348615
2024-09-09AVXL5.1350.220.0149104
2024-09-10AVXL5.010.220.0950120
2024-09-11AVXL5.120.220.0250616
2024-09-12AVXL5.220.220.1350547
2024-09-13AVXL5.30.220.0550813
2024-09-16AVXL5.70.210.1350419
2024-09-17AVXL5.460.210.0550736
2024-09-18AVXL5.510.210.2350997
2024-09-19AVXL5.760.210.0951398
2024-09-20AVXL5.660.210.2351507
2024-09-23AVXL5.490.210.1349869
2024-09-24AVXL5.560.210.1450437
2024-09-25AVXL5.450.210.0151048
2024-09-26AVXL5.680.210.0651363
2024-09-27AVXL5.680.210.1451501
2024-09-30AVXL5.680.200.0051882
2024-10-01AVXL5.450.200.0152078
2024-10-02AVXL5.660.200.1352743
2024-10-03AVXL5.610.200.0052966
2024-10-04AVXL5.590.200.0153137
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-09-06AVXL5.15-33.3-11.8-0.54
2024-09-09AVXL5.14-33.3-18.3-0.54
2024-09-10AVXL5.01-33.3-15.8-0.54
2024-09-11AVXL5.12-33.3-20.2-0.54
2024-09-12AVXL5.22-33.3-19.7-0.54
2024-09-13AVXL5.30-33.3-19.7-0.54
2024-09-16AVXL5.71-33.3-24.7-0.54
2024-09-17AVXL5.45-33.3-14.5-0.54
2024-09-18AVXL5.51-33.3-18.8-0.54
2024-09-19AVXL5.77-33.3-22.2-0.54
2024-09-20AVXL5.66-33.3-16.6-0.54
2024-09-23AVXL5.49-33.3-16.0-0.54
2024-09-24AVXL5.55-33.3-19.1-0.54
2024-09-25AVXL5.45-33.3-16.5-0.54
2024-09-26AVXL5.67-33.3-21.7-0.54
2024-09-27AVXL5.68-33.3-18.3-0.54
2024-09-30AVXL5.67-33.3-18.0-0.54
2024-10-01AVXL5.45-33.3-14.8-0.54
2024-10-02AVXL5.65-33.3-21.5-0.54
2024-10-03AVXL5.60-33.3-17.4-0.54
2024-10-04AVXL5.59-33.3-18.1-0.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-09-06AVXL-2.39-1.9824.05
2024-09-09AVXL-2.39-1.9824.05
2024-09-10AVXL-2.39-1.9824.05
2024-09-11AVXL-2.39-1.9824.05
2024-09-12AVXL-2.39-1.9823.61
2024-09-13AVXL-2.39-1.9823.61
2024-09-16AVXL-2.39-1.9823.61
2024-09-17AVXL-2.39-1.9823.61
2024-09-18AVXL-2.39-1.9823.61
2024-09-19AVXL-2.39-1.9823.61
2024-09-20AVXL-2.39-1.9823.61
2024-09-23AVXL-2.39-1.9823.61
2024-09-24AVXL-2.39-1.9823.61
2024-09-25AVXL-2.39-1.9823.88
2024-09-26AVXL-2.39-1.9823.88
2024-09-27AVXL-2.39-1.9823.88
2024-09-30AVXL-2.39-1.9823.88
2024-10-01AVXL-2.39-1.9823.88
2024-10-02AVXL0.29-1.9823.88
2024-10-03AVXL0.29-1.9823.88
2024-10-04AVXL0.29-1.9823.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.14

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

0.29

Institutional Transactions

-1.98

Beta

0.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value (Academic)

Quality Score

11

Growth Score

19

Sentiment Score

44

Actual DrawDown %

82.2

Max Drawdown 5-Year %

-88.3

Target Price

33.67

P/E

Forward P/E

PEG

P/S

P/B

3.65

P/Free Cash Flow

EPS

-0.5

Average EPS Est. Cur. Y​

-0.54

EPS Next Y. (Est.)

-0.63

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.44

Return on Equity vs Sector %

-53.6

Return on Equity vs Industry %

-74.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-18.1
Anavex Life Sciences Corp.
Sector: Healthcare
Industry: Biotechnology
Employees: 40
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
stock quote shares AVXL – Anavex Life Sciences Corp. Stock Price stock today
news today AVXL – Anavex Life Sciences Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch AVXL – Anavex Life Sciences Corp. yahoo finance google finance
stock history AVXL – Anavex Life Sciences Corp. invest stock market
stock prices AVXL premarket after hours
ticker AVXL fair value insiders trading